Interface Biologics is a cutting-edge brand that specializes in the development of sustained drug delivery solutions for ophthalmic therapeutics. With their innovative Epidel™ technology, they have revolutionized the field by engineering controlled release Pharmaceuticals and Medical Device Coatings without the need for polymers or excipients. Their lead product, IBE-814 IVT, is a fully degradable intravitreal dexamethasone prodrug implant that targets DME, RVO, and NIU indications.

Interface Biologics' novel approach to drug delivery provides better outcomes for patients, simplifies care management for physicians, and reduces costs for payors. By designing prodrugs that can deliver themselves, they have created implantable forms such as cylinders and microspheres with highly tunable drug release and duration. This allows for precise control of drug dosing without the bulk added by a polymer.

Driven by their commitment to innovation, Interface Biologics has overcome the constraints of traditional drug delivery methods. With their minimalistic approach and simple, scalable, and cost-effective manufacturing processes, they are revolutionizing the pharmaceutical industry. Their vision has attracted strategic partnerships and licensing agreements, ensuring the global expansion of their groundbreaking technology.

For a future where drug delivery is optimized, Interface Biologics is at the forefront of the revolution